IntelliseqS.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2021-12-31
Share capital
3 032 404,50 PLN
Activity description

Intelliseq is a company that provides a cloud-based platform for the analysis of Next-Generation Sequencing (NGS) data and clinical interpretation. Their services include automated genomic analysis and reporting through products like iFlow™ and GeneSpect™ Reporters, which cover various medical conditions such as hereditary cancers and cardiovascular diseases. The platform is designed for ease of use, allowing users to perform analyses without needing extensive expertise.

Registered address
ul. Stanisława Konarskiego 42/13, 30-046 Kraków, Poland
Website
intelliseq.plWebsite active
Electronic delivery address
AE:PL-66195-56580-IIBFF-14

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 156.55kMedianUSD 38.31kAverageUSD 2.31m
Net profit
This companyUSD -968.45kMedianUSD -1.50kAverageUSD -84.98k
Operating costs
This companyUSD 1.11mMedianUSD 56.25kAverageUSD 2.29m
Assets
This companyUSD 2.74mMedianUSD 116.77kAverageUSD 2.72m

Bank accounts

Registered as a VAT taxpayer on 2014-09-30. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication dateEvent
May 30, 2025Shareholders' meeting convened
Jun 3, 2024Shareholders' meeting convened
Jun 2, 2023Shareholders' meeting convened

Public aid

11 public aid cases recorded, with a total value of $3,418,000.

Grant datePurposeGross amountGranting body
Oct 4, 2022
Aid for SME access to finance — risk finance aid
—PFR Ventures sp. z o.o.
Nov 12, 2019
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
—Prezes Polskiej Agencji Rozwoju Przedsiębiorczości
Aug 5, 2019
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
—Fundacja Instytut Studiów Wschodnich

European Funds

4 projects co-financed from European Funds recorded, with total EU co-financing of $1,880,474.

StartProjectEU co-financingProgramme
2019-10-01
Opracowanie systemu farmakologicznej interpretacji genomu - PGx Plus
$869,306Program Operacyjny Inteligentny Rozwój
2019-04-08
Promocja produktów informatyki genetycznej marki Intelliseq na rynku amerykańskim
$79,094Program Operacyjny Inteligentny Rozwój
2019-01-01
Opracowanie innowacyjnej technologii wytwarzania aplikacji mobilnych dla genetyki konsumenckiej - MOBIGEN
$420,277Regionalny Program Operacyjny Województwa Małopolskiego na lata 2014-2020

Tenders

No recorded participation in tenders.

Authorized Representatives

Klaudia Szklarczyk Smolana — President of the Management Board
Marcin Piechota — Vice President

Manner of representation

If the company has a one-person management board, it will be represented by one member (the President) of the management board, whereas if it has a multi-member management board, it will be represented as follows: A. by two members of the management board jointly; B. notwithstanding the foregoing provisions, if a member of the management board serving as Financial Director is appointed, the company will be represented by two members of the management board acting jointly, one of whom will be the member of the management board serving as Financial Director.

Supervisory board

Aleksander Kłósek — Supervisory Board Member
Dominik Herberholz — Supervisory Board Member
Michał Korostyński — Supervisory Board Member
Luiza Nowacka Samczuk — Supervisory Board Member
Magdalena Surowiec — Supervisory Board Member

Beneficial owners

PersonRights
Bartosz Drabikowski (56)
Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5).
Adam Żelezik (51)
Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5).

Competitors

NameRevenueWebsite
Digital Pathology Team Witold Reznersp. k.$383,078.99digitalpathologyteam.com
Medicofarma BiotechS.A.$314,882.33medicofarmabiotech.pl
Explorna Therapeuticssp. z o.o.$304,662.00explorna.com
Dicellasp. z o.o.$206,073.49dicella.com
Nexbiosp. z o.o.$186,582.40nexbio.pl
AI Corelabsp. z o.o.$106,857.00aicorelab.com
GMT GenomicsS.A.$89,076.86genomtec.com
Sfpesp. z o.o.$72,850.26sfpe.co.pl
Xenstatssp. z o.o.$66,774.27xenstats.com
Digital Pathology Teamsp. z o.o.$64,552.91digitalpathologyteam.com

Change history

DateEvent
2025-11-28Share capital change (3,014,404.50 PLN → 3,032,404.50 PLN)
2025-09-19Share capital change (2,930,595.50 PLN → 3,014,404.50 PLN)
2025-05-19Share capital change (2,672,404.50 PLN → 2,930,595.50 PLN)
2025-02-28Share capital change (1,827,409.00 PLN → 2,672,404.50 PLN)
2022-12-30Share capital change (1,250,220.00 PLN → 1,827,409.00 PLN)

FAQ

Last updated: 2026-10-03